Privacyvoorkeur

MEDtalks houdt u graag op de hoogte van de laatste ontwikkelingen op uw interessegebied. Kies hieronder of u op de hoogte gehouden wilt blijven van de nieuwste programma's en nascholingen binnen uw interessegebieden. Klik hier voor meer informatie.


EHA 2020: Journaal AML / MDS

Bekijk hier het MEDtalks EHA-journaal over het AML en MDS. In dit journaal bespreekt prof. dr. Gerwin Huls zijn highlights van EHA 2020.

Het nieuws wordt besproken aan de hand van onderstaande EHA-abstracts:

  1. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF VENETOCLAX WITH AZACITIDINE VS AZACITIDINE IN TREATMENT-NAÏVE PATIENTS WITH ACUTE MYELOID LEUKEMIA INELIGIBLE FOR INTENSIVE THERAPY-VIALE-A 
  2. THE ANEMIA-INDEPENDENT EFFECT OF MYELODYSPLASTIC SYNDROMES ON HEALTH-RELATED QUALITY OF LIFE 
  3. A PHASE III PLACEBO-CONTROLLED TRIAL OF CC-486 IN PATIENTS WITH RED BLOOD CELL TRANSFUSION-DEPENDENT (RBC-TD) ANEMIA AND THROMBOCYTOPENIA DUE TO IPSS LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) 
  4. PHASE 2 STUDY OF PEVONEDISTAT + AZACITIDINE VERSUS AZACITIDINE IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES/CHRONIC MYELOMONOCYTIC LEUKEMIA OR LOW-BLAST ACUTE MYELOGENOUS LEUKEMIA 
  5. THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY MAGROLIMAB COMBINED WITH AZACITIDINE IS WELL-TOLERATED AND EFFECTIVE IN MDS PATIENTS: PHASE 1B RESULTS 
  6. THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY MAGROLIMAB COMBINED WITH AZACITIDINE IS WELL-TOLERATED AND EFFECTIVE IN AML PATIENTS: PHASE 1B RESULTS 
  7. APR-246 COMBINED WITH AZACITIDINE IN TP53 MUTATED MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOID LEUKEMIA. A PHASE 2 STUDY BY THE GROUPE FRANCOPHONE DES MYÉLODYSPLASIES (GFM) 
  8. 10-DAY DECITABINE AND VENETOCLAX (DEC10-VEN) VS. INTENSIVE CHEMOTHERAPY (IC) IN ACUTE MYELOID LEUKEMIA (AML): A PROPENSITY SCORE MATCHED ANALYSIS STRATIFIED BY RISK OF TREATMENT-RELATED MORTALITY 
  9. ENASIDENIB PLUS AZACITIDINE SIGNIFICANTLY IMPROVES COMPLETE REMISSION AND OVERALL RESPONSE RATES VERSUS AZACITIDINE MONOTHERAPY IN MUTANT-IDH2 NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (ND-AML) 
  10. PHASE IB/II STUDY OF THE IDH1-MUTANT INHIBITOR IVOSIDENIB WITH THE BCL2 INHIBITOR VENETOCLAX +/- AZACITIDINE IN IDH1-MUTATED HEMATOLOGIC MALIGNANCIES 
  • Sponsoren

    Dit programma komt onafhankelijk tot stand en wordt financieel mogelijk gemaakt door

Gerelateerde publicaties